Adapting Pharmacoeconomics to Shape Efficient Health Systems en Route to UHC – Lessons from Two Continents
Open Access
- 10 October 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
Pharmacoeconomics is receiving increasing attention globally as a set of tools ensuring efficient use of resources in health systems, albeit with different applications depending on the contextual, cultural and development stages of each country. The factors guiding design, implementation and optimisation of pharmacoeconomics as a steering tool under the universal health coverage paradigm are explored using case studies of Germany and South Africa. Findings German social health insurance is subject to the efficiency precept. Pharmaco-regulatory tools reflect the respective framework conditions under which they developed at particular points in time. The institutionalisation of pharmacoeconomics and its integration into the remit of the Institute for Quality and Efficiency in Health Care occurred only rather recently. The road has not been smooth, requiring political discourse and complex processes of negotiation. Although enshrined in the National Drug Policy of 1996, South Africa, has had a more fragmented approach to medicine selection and pricing with different policies in private and public sectors. The regulatory reform for use of pharmacoeconomic tools is ongoing and will be further shaped by the introduction of National Health Insurance. Conclusion A clear vision or framework is essential as the introduction of pharmacoeconomics into regulation is not a single event but rather a growing momentum. The path will always be subject to influences of politics, economics and market forces beyond the healthcare system so delays and modifications to pharmacoeconomic tools are to be expected. Health systems are dynamic and pharmacoeconomic reforms needs to be sufficiently flexible to evolve alongside.This publication has 16 references indexed in Scilit:
- Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?Value in Health, 2017
- The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment OptionsValue in Health, 2017
- Cost–effectiveness thresholds: pros and consBulletin of the World Health Organization, 2016
- Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South AfricaPharmacoEconomics, 2015
- National Health Insurance in South Africa: Relevance of a national priority-setting agencySouth African Medical Journal, 2015
- Paying for and receiving benefits from health services in South Africa: is the health system equitable?Health Policy and Planning, 2012
- IQWiG methods--a response to two critiques.Health Economics, 2010
- Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approachHealth Economics, 2010
- Reimbursement of pharmaceuticals: reference pricing versus health technology assessmentThe European Journal of Health Economics, 2010
- The efficiency frontier approach to economic evaluation of health‐care interventionsHealth Economics, 2010